Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson raked in $100 million in first-quarter sales from its single-shot COVID-19 vaccine that was put on hold last week by the U.S. Food and Drug Administration.

Johnson & Johnson coronavirus vaccine delivers $100M in sales

J&J's financial results come as the company's Covid-19 vaccine has been put on pause in the United States.

Johnson & Johnson reports $100 million in quarterly sales from Covid vaccine

Johnson & Johnson reported Tuesday first-quarter profit and sales that rose above expectations, citing strength in its pharmaceutical business and continued recovery in medical devices. The drug giant's stock slipped 0.2% in premarket trading.

J&J beats profit and sales expectations, boosts dividend; COVID-19 vaccine adds $100 million to sales

Johnson & Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday.

Johnson & Johnson reports $100 million in quarterly COVID-19 vaccine sales

NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021.

Johnson & Johnson Reports 2021 First-Quarter Results:

NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend, from $1.01 per share to $1.06 per share.

Johnson & Johnson Announces Dividend Increase of 5.0%

AbbVie

Endo International

Teva Pharmaceutical

Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of multibillion-dollar trial.

J&J, other drugmakers go to trial in California in $50 billion case over 'deadly legacy' of opioids

Formally addressing the recent challenges will help to put shareholders at ease again.

2 Things Investors Need to Look For in Johnson & Johnson's Earnings Tomorrow

Johnson & Johnson stock is scheduled to report its Q1 2021 results on Tuesday, April 20. We expect J&J to report revenues and earnings slightly below the consensus estimates.

Can Johnson & Johnson Stock Rise Post Q1 Results?

How much will the healthcare giant suffer, and what does this mean for worldwide vaccination efforts?

What Does J&J's Pause Mean for Investors?

American Express

Dow Inc

Honeywell

Verizon

We have narrowed down our search to five blue-chip stocks slated to release first-quarter earnings results this week. These are: DOW, JNJ, HON, AXP and VZ.

5 Blue-Chip Stocks Likely to Gain on Q1 Earnings This Week

U.S. health authorities came close to simply warning about a blood-clotting risk from Johnson & Johnson's COVID-19 vaccine, but decided to recommend pausing use out of concern doctors would improperly treat the condition, people familiar with the matter said.

The Wall Street Journal: J&J vaccine was paused due to fear blood clots could be mistreated

Chipotle

Intel

Netflix

AT&T

Procter & Gamble

It's a busy week of earnings with Coca-Cola, IBM, Netflix, Procter & Gamble, Chipotle, Verizon, AT&T, Intel, and American Express among 72 S&P 500 firms reporting.

AT&T, Netflix, Intel, Chipotle, and Other Stocks to Watch This Week

Health regulators have asked states to temporarily halt J&J's single-dose shot after reports of six cases of rare brain blood clots in women.

Fauci says U.S. will likely resume use of J&J Covid vaccine with a warning or restriction

“I don't think it's just going to go back and say, ‘Okay, everything's fine. Go right back,'” said Biden's chief medical advisor.

Fauci Predicts J&J Vaccine Will Be Back This Week—But With New ‘Warning' Or ‘Restriction'

Dr. Anthony Fauci, the nation's top infectious disease expert, said he hopes there's a decision on the paused Johnson & Johnson vaccine by Friday. "I do think we will get it back in some manner or form, but what I hope that we don't see anything beyond Friday," Fauci told Dana Bash on CNN's "State of the Union" Sunday.

Fauci hopeful on upcoming Johnson & Johnson vaccine decision: 'We will get it back in some manner or form'

The pause on the use of the J&J Covid vaccine may not slow the overall U.S. vaccine rollout, but could make it tougher for some populations to get a shot.

Johnson & Johnson vaccine pause makes it tougher to immunize hard-to-reach populations against Covid

The drugmaker says there's not enough evidence to establish a causal link between its vaccine and six cases of blood clots, which US officials say "appear to be extremely rare."

Johnson & Johnson scientists push back on coronavirus vaccine pause

Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday, citing people familiar with the situation. Only AstraZeneca agreed, according to the WSJ.

J&J reportedly sought help from rivals after blood clot concerns emerged

Lockheed Martin

Philip Morris

More than 300 publicly traded companies are expected to report March quarter earnings next week as earnings season revs up.

Earnings Previews: Johnson & Johnson, Lockheed, Philip Morris, Procter & Gamble

To what degree will Johnson & Johnson's COVID-19 vaccine manufacturing issues and the federal 'pause' over safety concerns weigh on investors' mind when the company reports earnings next week?

Earnings Outlook: Here's how the ‘pause' on J&J's COVID-19 shot may affect the company's earnings

A Centers for Disease Control and Prevention's advisory committee is scheduled to meet for a second time on Friday, April 23, to discuss rare safety concerns about Johnson & Johnson's COVID-19 vaccine. Of the 6.8 million people in the U.S. who have received the J&J's shot, six women have been hospitalized with severe blood clots after receiving the vaccine.

CDC committee to meet again on April 23 to discuss J&J's COVID-19 shot

Moderna

Pfizer

J&J asked Covid vaccine rivals Pfizer and Moderna to join a study looking into the potential risk of blood clots, the Wall Street Journal reported.

J&J asked Pfizer and Moderna to help study blood-clot risks but they declined, report says

In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.

Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?

AstraZeneca

The Norwegian government said it needs more time to decide whether to restart the use of AstraZeneca's COVID-19 vaccine, or permanently remove it from the country's immunization program.

News for Johnson & Johnson Stock (JNJ)